Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO)La Merie PublishingNovember 1, 2009 18 Pages - SKU: LAM2496160 |
| The Competitive Intelligence Report Thrombopoiesis Stimulating Agents (TPO, IL-11) as of November 2009 provides information on thrombopoiesis stimulating agents targeting the thrombopoietin, interleukin-11 or other receptors on the market and in development. The product portfolio and R&D pipeline includes six products on the market, further eight clinical stage and further ten preclinical new molecules in various indications from the product categories antibody, protein, peptide and small molecule (NCE). Thrombopoiesis stimulating agents are under evaluation for treatment of idiopathic thrombocytopenic purpura (ITP) and for prevention of severe thrombocytopenia induced by chemotherapy. The report includes a compilation of marketed products and current active projects in research and development of molecules targeting the TPO, IL-11 or other receptors. In addition, the report lists company-specific product portfolio and R&D pipelines of thrombopoiesis stimulating agents. Competitor projects are listed in a tabular format providing information on:
|
Related Markets
Drug Discovery Reports
- Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Patient Perspectives - Patient Reported Outcomes Drive Drug Development, but Improving Patient Involvement Remains a Challenge
- Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
- Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
- Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2012
